Published in J Neurosci on November 14, 2007
Can Alzheimer disease be prevented by amyloid-beta immunotherapy? Nat Rev Neurol (2010) 2.20
Reducing AD-like pathology in 3xTg-AD mouse model by DNA epitope vaccine - a novel immunotherapeutic strategy. PLoS One (2008) 1.42
DNA prime-protein boost increased the titer, avidity and persistence of anti-Abeta antibodies in wild-type mice. Gene Ther (2009) 1.13
Frontal cortex neuropathology in dementia pugilistica. J Neurotrauma (2012) 1.08
Amyloid-beta immunotherapy for Alzheimer's disease. CNS Neurol Disord Drug Targets (2010) 1.07
Immunotherapy for Alzheimer disease: the challenge of adverse effects. Nat Rev Neurol (2012) 1.05
Abeta DNA vaccination for Alzheimer's disease: focus on disease prevention. CNS Neurol Disord Drug Targets (2010) 1.02
How to get from here to there: macrophage recruitment in Alzheimer's disease. Curr Alzheimer Res (2011) 1.02
Immunogenicity, efficacy, safety, and mechanism of action of epitope vaccine (Lu AF20513) for Alzheimer's disease: prelude to a clinical trial. J Neurosci (2013) 1.02
Analysis of three plasmid systems for use in DNA A beta 42 immunization as therapy for Alzheimer's disease. Vaccine (2010) 1.00
Mannan-Abeta28 conjugate prevents Abeta-plaque deposition, but increases microhemorrhages in the brains of vaccinated Tg2576 (APPsw) mice. J Neuroinflammation (2008) 0.97
Refinement of a DNA based Alzheimer's disease epitope vaccine in rabbits. Hum Vaccin Immunother (2013) 0.94
DNA epitope vaccine containing complement component C3d enhances anti-amyloid-beta antibody production and polarizes the immune response towards a Th2 phenotype. J Neuroimmunol (2008) 0.94
Epitope-based DNA vaccine for Alzheimer's disease: translational study in macaques. Alzheimers Dement (2013) 0.92
Delivery of a DNA vaccine for Alzheimer's disease by electroporation versus gene gun generates potent and similar immune responses. Neurodegener Dis (2012) 0.90
Rationale for peptide and DNA based epitope vaccines for Alzheimer's disease immunotherapy. CNS Neurol Disord Drug Targets (2009) 0.89
A fresh perspective from immunologists and vaccine researchers: Active vaccination strategies to prevent and reverse Alzheimer's disease. Alzheimers Dement (2015) 0.89
The immunological potency and therapeutic potential of a prototype dual vaccine against influenza and Alzheimer's disease. J Transl Med (2011) 0.87
Antibodies to potato virus Y bind the amyloid beta peptide: immunohistochemical and NMR studies. J Biol Chem (2008) 0.84
The MultiTEP platform-based Alzheimer's disease epitope vaccine activates a broad repertoire of T helper cells in nonhuman primates. Alzheimers Dement (2014) 0.82
An N-terminal antibody promotes the transformation of amyloid fibrils into oligomers and enhances the neurotoxicity of amyloid-beta: the dust-raising effect. J Neuroinflammation (2015) 0.82
Linear and conformation specific antibodies in aged beagles after prolonged vaccination with aggregated Abeta. Neurobiol Dis (2010) 0.81
Immune complex formation impairs the elimination of solutes from the brain: implications for immunotherapy in Alzheimer's disease. Acta Neuropathol Commun (2013) 0.81
Immunogenicity of epitope vaccines targeting different B cell antigenic determinants of human α-synuclein: feasibility study. Neurosci Lett (2013) 0.80
Novel amyloid-beta specific scFv and VH antibody fragments from human and mouse phage display antibody libraries. J Neuroimmunol (2010) 0.80
Epitope analysis following active immunization with tau proteins reveals immunogens implicated in tau pathogenesis. J Neuroinflammation (2014) 0.80
Low concentrations of anti-Aβ antibodies generated in Tg2576 mice by DNA epitope vaccine fused with 3C3d molecular adjuvant do not affect AD pathology. Hum Gene Ther (2010) 0.78
Perspectives in molecular imaging using staging biomarkers and immunotherapies in Alzheimer's disease. ScientificWorldJournal (2013) 0.78
Alzheimer's disease Advax(CpG)- adjuvanted MultiTEP-based dual and single vaccines induce high-titer antibodies against various forms of tau and Aβ pathological molecules. Sci Rep (2016) 0.77
Immune-directed gene therapeutic development for Alzheimer's, prion, and Parkinson's diseases. J Neuroimmune Pharmacol (2008) 0.77
Immunostimulant patches containing Escherichia coli LT enhance immune responses to DNA- and recombinant protein-based Alzheimer's disease vaccines. J Neuroimmunol (2014) 0.77
Combined treatment of Aβ immunization with statin in a mouse model of Alzheimer's disease. J Neuroimmunol (2012) 0.76
Alzheimer's disease: is a vaccine possible? Braz J Med Biol Res (2014) 0.76
Comparison of Efficacy of Preventive and Therapeutic Vaccines Targeting the N Terminus of β-Amyloid in an Animal Model of Alzheimer's Disease. Mol Ther (2017) 0.75
A dual vaccine against influenza & Alzheimer's disease failed to enhance anti-β-amyloid antibody responses in mice with pre-existing virus specific memory. J Neuroimmunol (2014) 0.75
Amyloid-β immunization enhances neurogenesis and cognitive ability in neonatal mice. Int J Clin Exp Med (2015) 0.75
Yeast expressed foldable quadrivalent Aβ15 elicited strong immune response against Aβ without Aβ-specific T cell response in wild C57BL/6 mice. Hum Vaccin Immunother (2012) 0.75
MultiTEP platform-based DNA epitope vaccine targeting N-terminus of tau induces strong immune responses and reduces tau pathology in THY-Tau22 mice. Vaccine (2017) 0.75
MultiTEP platform-based DNA vaccines for alpha-synucleinopathies: preclinical evaluation of immunogenicity and therapeutic potency. Neurobiol Aging (2017) 0.75
The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science (2002) 49.51
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol (2004) 21.56
Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science (1996) 19.72
Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science (2003) 18.18
A specific amyloid-beta protein assembly in the brain impairs memory. Nature (2006) 16.19
Alzheimer's disease: the amyloid cascade hypothesis. Science (1992) 13.80
Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature (1999) 12.95
Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol (2007) 10.75
Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat Neurosci (2004) 9.73
Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med (2000) 8.89
The molecular pathology of Alzheimer's disease. Neuron (1991) 8.21
Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med (2003) 7.83
A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature (2001) 7.35
A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature (2001) 6.78
Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology (2003) 6.51
Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J Neurosci (2001) 6.32
Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A (2001) 5.60
Synthetic peptide vaccine design: synthesis and properties of a high-density multiple antigenic peptide system. Proc Natl Acad Sci U S A (1988) 5.52
Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology (2005) 5.51
Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat Neurosci (2002) 5.01
Formic acid pretreatment enhances immunostaining of cerebral and systemic amyloids. Lab Invest (1987) 4.98
Targeting small Abeta oligomers: the solution to an Alzheimer's disease conundrum? Trends Neurosci (2001) 4.92
Alzheimer's disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc Natl Acad Sci U S A (2003) 4.80
Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron (2003) 4.39
Beta-amyloid neurotoxicity requires fibril formation and is inhibited by congo red. Proc Natl Acad Sci U S A (1994) 4.33
The relationship between Abeta and memory in the Tg2576 mouse model of Alzheimer's disease. J Neurosci (2002) 4.27
Cerebral hemorrhage after passive anti-Abeta immunotherapy. Science (2002) 3.93
Glial fibrillary acidic protein: GFAP-thirty-one years (1969-2000). Neurochem Res (2000) 3.84
Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology (2005) 3.58
A learning deficit related to age and beta-amyloid plaques in a mouse model of Alzheimer's disease. Nature (2001) 3.28
Amyloid beta protein immunotherapy neutralizes Abeta oligomers that disrupt synaptic plasticity in vivo. Nat Med (2005) 3.28
Alzheimer's disease: a central role for amyloid. J Neuropathol Exp Neurol (1994) 3.19
Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease. Brain Pathol (2004) 3.01
Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides. Immunity (1994) 2.90
Abeta vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. Neurology (2005) 2.79
Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J Neuroinflammation (2004) 2.67
Apoptosis is induced by beta-amyloid in cultured central nervous system neurons. Proc Natl Acad Sci U S A (1993) 2.62
Epitope and isotype specificities of antibodies to beta -amyloid peptide for protection against Alzheimer's disease-like neuropathology. Proc Natl Acad Sci U S A (2003) 2.58
Evaluation of the safety and immunogenicity of synthetic Abeta42 (AN1792) in patients with AD. Neurology (2005) 2.58
Therapeutically effective antibodies against amyloid-beta peptide target amyloid-beta residues 4-10 and inhibit cytotoxicity and fibrillogenesis. Nat Med (2002) 2.49
A portrait of Alzheimer secretases--new features and familiar faces. Science (2001) 2.42
Amyloid-beta immunotherapy for Alzheimer's disease: the end of the beginning. Nat Rev Neurosci (2002) 2.42
Abeta species removal after abeta42 immunization. J Neuropathol Exp Neurol (2006) 2.25
Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta. J Neurosci (2005) 2.21
Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with beta-amyloid. Int Immunol (2003) 2.02
Amyloid-beta immunization effectively reduces amyloid deposition in FcRgamma-/- knock-out mice. J Neurosci (2003) 1.87
Cerebrospinal fluid amyloid beta42/phosphorylated tau ratio discriminates between Alzheimer's disease and vascular dementia. J Gerontol A Biol Sci Med Sci (2006) 1.85
Amyloid-beta peptide remnants in AN-1792-immunized Alzheimer's disease patients: a biochemical analysis. Am J Pathol (2006) 1.73
Inflammation and therapeutic vaccination in CNS diseases. Nature (2002) 1.58
Prototype Alzheimer's disease vaccine using the immunodominant B cell epitope from beta-amyloid and promiscuous T cell epitope pan HLA DR-binding peptide. J Immunol (2005) 1.56
Aggregation-related toxicity of synthetic beta-amyloid protein in hippocampal cultures. Eur J Pharmacol (1991) 1.56
Flow cytometric measurement of intracellular cytokines. J Immunol Methods (2000) 1.47
Reduced effectiveness of Abeta1-42 immunization in APP transgenic mice with significant amyloid deposition. Neurobiol Aging (2001) 1.39
Amyloid-beta vaccination, but not nitro-nonsteroidal anti-inflammatory drug treatment, increases vascular amyloid and microhemorrhage while both reduce parenchymal amyloid. Neuroscience (2006) 1.31
Anti-A beta 1-11 antibody binds to different beta-amyloid species, inhibits fibril formation, and disaggregates preformed fibrils but not the most toxic oligomers. J Biol Chem (2007) 1.30
Cellular and molecular biology of Alzheimer's disease and animal models. Annu Rev Med (1994) 1.24
Vaccination with amyloid-beta peptide induces autoimmune encephalomyelitis in C57/BL6 mice. Brain (2003) 1.15
Generation and characterization of the humoral immune response to DNA immunization with a chimeric beta-amyloid-interleukin-4 minigene. Eur J Immunol (2003) 1.12
Importance of IgG2c isotype in the immune response to beta-amyloid in amyloid precursor protein/transgenic mice. Neurosci Lett (2003) 1.09
Transcutaneous beta-amyloid immunization reduces cerebral beta-amyloid deposits without T cell infiltration and microhemorrhage. Proc Natl Acad Sci U S A (2007) 1.04
Immunogenic properties of multiple antigen peptide systems containing defined T and B epitopes. J Immunol (1992) 1.02
Chemical and immunological heterogeneity of fibrillar amyloid in plaques of Alzheimer's disease and Down's syndrome brains revealed by confocal microscopy. Am J Pathol (1995) 0.97
Oxidation of Abeta and plaque biogenesis in Alzheimer's disease and Down syndrome. Neurobiol Dis (2001) 0.97
Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science (2003) 18.18
Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet (2011) 10.07
A microfluidic culture platform for CNS axonal injury, regeneration and transport. Nat Methods (2005) 7.62
Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron (2004) 5.52
Fibril specific, conformation dependent antibodies recognize a generic epitope common to amyloid fibrils and fibrillar oligomers that is absent in prefibrillar oligomers. Mol Neurodegener (2007) 4.15
Reduction of soluble Abeta and tau, but not soluble Abeta alone, ameliorates cognitive decline in transgenic mice with plaques and tangles. J Biol Chem (2006) 2.33
Gene expression changes in the course of normal brain aging are sexually dimorphic. Proc Natl Acad Sci U S A (2008) 2.29
Memory loss in old rats is associated with brain mitochondrial decay and RNA/DNA oxidation: partial reversal by feeding acetyl-L-carnitine and/or R-alpha -lipoic acid. Proc Natl Acad Sci U S A (2002) 2.28
Soluble fibrillar oligomer levels are elevated in Alzheimer's disease brain and correlate with cognitive dysfunction. Neurobiol Dis (2009) 2.12
Novel late-onset Alzheimer disease loci variants associate with brain gene expression. Neurology (2012) 2.08
Annular protofibrils are a structurally and functionally distinct type of amyloid oligomer. J Biol Chem (2008) 2.04
Adjuvant-dependent modulation of Th1 and Th2 responses to immunization with beta-amyloid. Int Immunol (2003) 2.02
Retracted Human chromosome 21-derived miRNAs are overexpressed in down syndrome brains and hearts. Biochem Biophys Res Commun (2008) 1.91
Patterned cell culture inside microfluidic devices. Lab Chip (2004) 1.89
APOE epsilon2 is associated with intact cognition but increased Alzheimer pathology in the oldest old. Neurology (2009) 1.74
Microfluidic Multicompartment Device for Neuroscience Research. Langmuir (2003) 1.72
Alzheimer's disease is not "brain aging": neuropathological, genetic, and epidemiological human studies. Acta Neuropathol (2011) 1.62
Prototype Alzheimer's disease vaccine using the immunodominant B cell epitope from beta-amyloid and promiscuous T cell epitope pan HLA DR-binding peptide. J Immunol (2005) 1.56
Biliverdin reductase-A: a novel drug target for atorvastatin in a dog pre-clinical model of Alzheimer disease. J Neurochem (2011) 1.53
Retracted Chromosome 21-derived microRNAs provide an etiological basis for aberrant protein expression in human Down syndrome brains. J Biol Chem (2009) 1.53
Caspase-9 activation and caspase cleavage of tau in the Alzheimer's disease brain. Neurobiol Dis (2002) 1.51
Blocking Abeta42 accumulation delays the onset and progression of tau pathology via the C terminus of heat shock protein70-interacting protein: a mechanistic link between Abeta and tau pathology. J Neurosci (2008) 1.49
Reducing AD-like pathology in 3xTg-AD mouse model by DNA epitope vaccine - a novel immunotherapeutic strategy. PLoS One (2008) 1.42
Nutrition, brain aging, and neurodegeneration. J Neurosci (2009) 1.40
Exercise alters the immune profile in Tg2576 Alzheimer mice toward a response coincident with improved cognitive performance and decreased amyloid. J Neuroinflammation (2008) 1.38
Blocking IL-1 signaling rescues cognition, attenuates tau pathology, and restores neuronal β-catenin pathway function in an Alzheimer's disease model. J Immunol (2011) 1.36
Brain aging in the canine: a diet enriched in antioxidants reduces cognitive dysfunction. Neurobiol Aging (2002) 1.34
Conformation dependent monoclonal antibodies distinguish different replicating strains or conformers of prefibrillar Aβ oligomers. Mol Neurodegener (2010) 1.34
Size and reversal learning in the beagle dog as a measure of executive function and inhibitory control in aging. Learn Mem (2003) 1.32
The canine (dog) model of human aging and disease: dietary, environmental and immunotherapy approaches. J Alzheimers Dis (2008) 1.31
Anti-A beta 1-11 antibody binds to different beta-amyloid species, inhibits fibril formation, and disaggregates preformed fibrils but not the most toxic oligomers. J Biol Chem (2007) 1.30
Phagocytosis of amyloid-beta and inflammation: two faces of innate immunity in Alzheimer's disease. J Alzheimers Dis (2007) 1.28
Alzheimer disease and Down syndrome: factors in pathogenesis. Neurobiol Aging (2005) 1.24
Dissociation of neuropathologic findings and cognition: case report of an apolipoprotein E epsilon2/epsilon2 genotype. Arch Neurol (2007) 1.22
Caspase-mediated cleavage of glial fibrillary acidic protein within degenerating astrocytes of the Alzheimer's disease brain. Am J Pathol (2006) 1.20
Neurogenesis decreases with age in the canine hippocampus and correlates with cognitive function. Neurobiol Learn Mem (2007) 1.19
Locomotor activity rhythms in dogs vary with age and cognitive status. Behav Neurosci (2003) 1.19
Systemic mitochondrial dysfunction and the etiology of Alzheimer's disease and down syndrome dementia. J Alzheimers Dis (2010) 1.19
Lack of pathology in a triple transgenic mouse model of Alzheimer's disease after overexpression of the anti-apoptotic protein Bcl-2. J Neurosci (2008) 1.18
A transgenic Alzheimer rat with plaques, tau pathology, behavioral impairment, oligomeric aβ, and frank neuronal loss. J Neurosci (2013) 1.17
Proteomic identification of brain proteins in the canine model of human aging following a long-term treatment with antioxidants and a program of behavioral enrichment: relevance to Alzheimer's disease. Neurobiol Aging (2006) 1.17
Deficient liver biosynthesis of docosahexaenoic acid correlates with cognitive impairment in Alzheimer's disease. PLoS One (2010) 1.15
Neuropathological heterogeneity in frontotemporal lobar degeneration with TDP-43 proteinopathy: a quantitative study of 94 cases using principal components analysis. J Neural Transm (Vienna) (2009) 1.14
Generation and characterization of the humoral immune response to DNA immunization with a chimeric beta-amyloid-interleukin-4 minigene. Eur J Immunol (2003) 1.12
Caspase Activation in the Alzheimer's Disease Brain: Tortuous and Torturous. Drug News Perspect (2002) 1.10
Synaptic genes are extensively downregulated across multiple brain regions in normal human aging and Alzheimer's disease. Neurobiol Aging (2012) 1.10
ets-2 promotes the activation of a mitochondrial death pathway in Down's syndrome neurons. J Neurosci (2005) 1.09
Importance of IgG2c isotype in the immune response to beta-amyloid in amyloid precursor protein/transgenic mice. Neurosci Lett (2003) 1.09
Prototype Alzheimer's disease epitope vaccine induced strong Th2-type anti-Abeta antibody response with Alum to Quil A adjuvant switch. Vaccine (2005) 1.09
Frontal cortex neuropathology in dementia pugilistica. J Neurotrauma (2012) 1.08
ABCC9 gene polymorphism is associated with hippocampal sclerosis of aging pathology. Acta Neuropathol (2014) 1.07
Antitumor efficacy of DNA vaccination to the epigenetically acting tumor promoting transcription factor BORIS and CD80 molecular adjuvant. J Cell Biochem (2006) 1.07
Selective apoptosis of breast cancer cells by siRNA targeting of BORIS. Biochem Biophys Res Commun (2008) 1.03
Novel Abeta peptide immunogens modulate plaque pathology and inflammation in a murine model of Alzheimer's disease. J Neuroinflammation (2005) 1.03
Fas and Fas ligand are associated with neuritic degeneration in the AD brain and participate in beta-amyloid-induced neuronal death. Neurobiol Dis (2003) 1.03
Down syndrome and dementia: a randomized, controlled trial of antioxidant supplementation. Am J Med Genet A (2011) 1.02
Immunogenicity, efficacy, safety, and mechanism of action of epitope vaccine (Lu AF20513) for Alzheimer's disease: prelude to a clinical trial. J Neurosci (2013) 1.02
Accumulation of caspase cleaved amyloid precursor protein represents an early neurodegenerative event in aging and in Alzheimer's disease. Neurobiol Dis (2003) 1.02
Association between frontal cortex oxidative damage and beta-amyloid as a function of age in Down syndrome. Biochim Biophys Acta (2011) 1.02
Brain-derived neurotrophic factor-dependent synaptic plasticity is suppressed by interleukin-1β via p38 mitogen-activated protein kinase. J Neurosci (2012) 1.01
Region specific neuron loss in the aged canine hippocampus is reduced by enrichment. Neurobiol Aging (2006) 1.01
Frontal lobe volume, function, and beta-amyloid pathology in a canine model of aging. J Neurosci (2004) 1.01
Caspase-cleaved tau accumulation in neurodegenerative diseases associated with tau and alpha-synuclein pathology. Acta Neuropathol (2005) 1.00
Experimental investigation of antibody-mediated clearance mechanisms of amyloid-beta in CNS of Tg-SwDI transgenic mice. J Neurosci (2007) 1.00
Neuroprotective effects of cognitive enrichment. Ageing Res Rev (2006) 1.00
Early brain injury alters the blood-brain barrier phenotype in parallel with β-amyloid and cognitive changes in adulthood. J Cereb Blood Flow Metab (2012) 1.00
Reductions in amyloid-beta-derived neuroinflammation, with minocycline, restore cognition but do not significantly affect tau hyperphosphorylation. J Alzheimers Dis (2010) 1.00
Aging and cerebrovascular dysfunction: contribution of hypertension, cerebral amyloid angiopathy, and immunotherapy. Ann N Y Acad Sci (2010) 0.99
Beta-amyloid, oxidative stress and down syndrome. Curr Alzheimer Res (2006) 0.99
BDNF increases with behavioral enrichment and an antioxidant diet in the aged dog. Neurobiol Aging (2010) 0.99
Caspase activation in Alzheimer's disease: early to rise and late to bed. Rev Neurosci (2008) 0.98
A fibril-specific, conformation-dependent antibody recognizes a subset of Abeta plaques in Alzheimer disease, Down syndrome and Tg2576 transgenic mouse brain. Acta Neuropathol (2009) 0.98